New hope for advanced colon cancer patients who've run out of options

NCT ID NCT07515820

Not yet recruiting Disease control Sponsor: Meng Qiu Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new drug, SHR-3821, combined with fruquintinib in 12 people with advanced colorectal cancer that has not responded to at least two standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow the disease. This is not a cure, but aims to control the cancer for as long as possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••